Nerve Fiber Density Testing
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage for skin biopsy–based nerve fiber density testing (eg, epidermal/intraepidermal nerve fiber density and sweat gland nerve fiber density) for evaluation of small-fiber neuropathy and related indications for Blue Cross Blue Shield Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Diagnosis of small-fiber neuropathy — Covered when ALL of the following are met
Covered when ALL of the following are met:
These four elements must all be present for ENFD measurement to meet coverage criteria.
inv-02: Covered when guideline-supported clinical suspicion of SFN exists — guideline-supported uses and clinical contexts where skin biopsy / IENFD testing is recommended or described
Guideline-supported uses and clinical contexts where skin biopsy / IENFD testing is recommended or described:
Supported by AAN/AANEM/AAPM&R and EFNS/PNS statements
Reference: EFNS guidance
Supported by AACE/ACE and ADA statements
IMMPACT and EFNS observations
inv-03: Clinical guidance references — clinical guideline statements relevant to when IENFD/skin biopsy is indicated
Clinical guideline statements relevant to when IENFD/skin biopsy is indicated:
Recommendation from NeuPSIG/IASP
Statements from ADA and NeuPSIG
IMMPACT guidance
Skin biopsy with epidermal nerve fiber density (ENFD/IENFD) measurement is explicitly not covered for indications other than the documented diagnostic criteria for small‑fiber neuropathy. This exclusion includes, but is not limited to, use for routine surveillance, general monitoring of disease progression, or evaluation outside the specific diagnostic scenario where all coverage criteria are met.
Measurement of sweat gland nerve fiber density (SGNF/SGNFD) is stated in the policy as not meeting coverage criteria and therefore is excluded from coverage.
Guidance cited in the policy notes that while skin biopsy with IENFD quantification is a validated technique for detecting small fiber pathology, it has limited utility for identifying the underlying etiology of small‑fiber neuropathy. EFNS/PNS specifically states that skin biopsy has not so far been useful for determining etiology and cautions that IENFD does not correlate well with pain intensity, limiting its role in explaining cause in many cases.
An international expert panel addressing peripheral nervous system involvement in Fabry disease concluded that, because accurate laboratory diagnostic tests are available, nerve or skin biopsies are not required for the diagnosis of Fabry disease.
Published data indicate that assessment of small nerve fibers alone cannot reliably establish a diagnosis of Fabry disease in patients with certain alpha‑Galactosidase A variants. The cited study concluded that small‑fiber testing cannot confirm Fabry disease in these variant carriers and should not be used in isolation for diagnosis.
The policy specifies that use of skin biopsy ENFD for serial assessment—such as monitoring disease progression or assessing response to treatment—does not meet coverage criteria and will not be covered.
In a retrospective study of patients with erythromelalgia, investigators found that few had decreased ENFD and concluded that skin biopsy for ENFD was not useful for diagnosing erythromelalgia; functional nerve testing was recommended as the preferred diagnostic approach.
Reinforcing prior statements, the expert panel on Fabry disease emphasizes that skin or nerve biopsy is not required to diagnose Fabry disease when accurate laboratory diagnostic tests are available; biopsy may detect small‑fiber involvement but is not necessary for diagnosis.
The policy cites evidence that small nerve fiber assessment alone is insufficient to confirm Fabry disease in some genetic variants, underscoring that biopsy or small‑fiber testing should not replace appropriate laboratory genetic or enzymatic testing for definitive diagnosis.
Coding
| No codes listed |
| No codes listed |
| No codes listed |
Provider Actions and Documentation
Prior Authorization Not Specified
Prior authorization not specified in the excerpt. The policy text does not state a payer-mandated prior authorization requirement for skin biopsy with epidermal nerve fiber density (IENFD) measurement.
- Prior authorization not specified in excerpt
LDT Status and Administrative Considerations
Laboratory-developed tests (LDTs) for IENFD are commonly performed by individual laboratories and are regulated under CLIA as high-complexity LDTs. These tests are not FDA-cleared or -approved for clinical use but may be used clinically; administrative considerations (e.g., lab validation and billing practices) may apply at the payer or laboratory level.
- LDT status: regulated under CLIA as high-complexity tests
- FDA clearance/approval not required for clinical use
No Payer-Mandated Authorization Specified
No explicit procedural or payer prior-authorization triggers are specified in the guidance sections reproduced here. Clinical guideline recommendations are described, but they do not establish payer-mandated authorization workflows in this excerpt.
- No explicit procedural/prior authorization triggers in excerpt
Government Policy Precedence
Government policies (e.g., Medicare Local Coverage Determinations or National Coverage Determinations, and applicable state Medicaid rules) take precedence over this policy when conflicts exist. For final determinations for government beneficiaries, refer to the current CMS and state Medicaid resources.
- Government policy precedence: LCDs/NCDs and state Medicaid prevail in case of conflict
- CMS Medicare Coverage Database: https://www.cms.gov/medicare-coverage-database/search.aspx
Adopted Reimbursement Policy Effective 7/1/2023
This policy follows the adopted Avalon reimbursement policy recommendation effective 7/1/2023. Failure to follow the adopted reimbursement policy when applicable may result in claim denials per payer rules.
- Adopted Avalon policy recommendation effective 7/1/2023
Required Documentation Elements
Required documentation should support the clinical indication for small-fiber testing. Documentation elements include the patient's clinical presentation (e.g., painful sensory neuropathy), history excluding disorders that predispose to painful neuropathy, focused physical exam findings, and results of large-fiber testing (electromyography/nerve conduction studies) when indicated.
- Document clinical presentation of painful sensory neuropathy
- Document absence of history of disorders known to predispose to painful neuropathy (e.g., diabetic, toxic, HIV, celiac, inherited)
- Document physical exam showing no evidence of large-fiber neuropathy (reflexes, proprioception, vibration)
- Include EMG/nerve conduction study results showing no large-fiber neuropathy when required by coverage criteria
Skin Punch Biopsy Technique
Skin punch biopsy using a 3-mm punch is described as a validated, minimally invasive technique to obtain skin tissue for quantifying intraepidermal nerve fiber (IENF) density. Specimens are typically stained (e.g., PGP 9.5) and evaluated using generally agreed counting rules.
- 3-mm skin punch biopsy described as validated, minimally invasive technique
- Specimen stained with PGP 9.5 and quantified using agreed counting rules
Clinical Indication Documentation
Clinical indication documentation must support assessment of small-fiber dysfunction. The policy requires: history of symptoms consistent with small-fiber neuropathy (for diagnosis of SFN) and documentation that other causes/predisposing conditions have been considered and excluded per coverage criteria.
- Clinical documentation should support small-fiber dysfunction (history of painful sensory neuropathy)
- Documentation must show exclusion of disorders that predispose to painful neuropathy
Clinical Findings to Reference in Documentation
Documentation should reference specific clinical indications for small-fiber testing such as suspected small fiber neuropathy, including relevant history and focused small-fiber examination findings (e.g., temperature or pinprick sensation deficits).
- Reference suspected small fiber neuropathy as indication
- Include relevant history and small-fiber exam findings such as temperature or pinprick deficits
Bedside Clinical Testing Should Precede Specialized Testing
Clinical bedside testing (e.g., 10-g monofilament, 128-Hz tuning fork, temperature or pinprick testing, ankle reflexes) is recommended as part of the assessment and generally precedes specialized testing such as skin biopsy for IENFD. Guideline statements emphasize performing simple clinical assessments before or alongside referral for specialized testing.
- Bedside testing: 10-g monofilament, 128-Hz tuning fork, temperature or pinprick testing, ankle reflexes
- Clinical/bedside testing precedes specialized testing like skin biopsy
Administrative Requirements Not Specified
Not specified in this section of the document: any additional payer administrative requirements (e.g., specific forms, precertification codes) beyond the coverage criteria and CLIA/LDT considerations noted elsewhere in the policy excerpt.
- Not specified in this section of the document
Background
Small‑fiber neuropathy affects small sensory and autonomic fibers that are often not detected on routine nerve‑conduction studies. The policy discusses skin punch biopsy with PGP 9.5 immunohistochemistry to quantify intraepidermal/epidermal nerve fiber density (IENFD/ENFD) as a validated, minimally invasive method to identify small‑fiber pathology and support the diagnosis of small‑fiber neuropathy when other testing is unrevealing.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.